ImmunoCellular Therapeutics (IMUC) Tops Q1 EPS by 1c

ImmunoCellular Therapeutics (NYSE: IMUC) reported Q1 EPS of ($0.06), $0.01 better than the analyst estimate of ($0.07).

For earnings history and earnings-related data on ImmunoCellular Therapeutics (IMUC) click here.

You May Also Be Interested In

• Trump discloses over $1.4 billion in crypto income in 2025 filing
• Baird starts Abbott at Outperform, sees product pipeline driving growth
• Whirlpool to close Mexico plant, expects $165M restructuring cost